Two-step target recognition for the competitive inhibition activity of an anti-VEGF aptamer.

Le résumé fourni par la source

The anti-vascular endothelial growth factor (VEGF) aptamer, t44.27, is a 27-mer RNA that functions as the active component of pegaptanib, an anti-angiogenic medicine for neovascular age-related macular degeneration. The t44.27 aptamer is extensively 2′-modified and tightly binds to the heparin-binding domain (HDB) of VEGF165 in a Ca2+-dependent manner. However, the molecular mechanism by which the aptamer selectively recognizes VEGF HDB to antagonize its function is poorly understood. We found that t44.27 binds to VEGF HBD in a two-step manner using a different region in the molecule: a transient interaction using a structured region of t44.27 followed by a tight-complex formation with a larger interaction surface. Ca2+ binding stabilizes t44.27 base-pair formation suitable for the initial transient interaction. Meanwhile, the tight-complex formation was essential for t44.27 to exert a competitive inhibition of heparin binding to VEGF HBD. These results provide structural insight into how the RNA aptamer specifically interacts with its target molecule to inhibit its activity.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.